SOURCE: SRI International

October 19, 2007 08:00 ET

SRI International Executive Walter Moos to Address Current Issues in Pharmaceutical Development

HARRISONBURG, VA--(Marketwire - October 19, 2007) - How long does it take to develop a new drug successfully? What drives drug discovery and development costs? What is the best way to navigate the ever-changing environment of drug discovery? Walter Moos, vice president of SRI International's Biosciences Division, will address these questions during a lecture on Tuesday, Oct. 23 at 5 p.m. at James Madison University (JMU).

Moos' presentation, which is free and open to the public, will be held in Room 2301 of the Health and Human Services Building east of Interstate 81. Parking will be available in Lot D-2 across from the building.

SRI International is one of the world's largest independent, nonprofit research and development organizations, originally founded as the Stanford Research Institute in 1946. In December 2006, SRI announced its new Center for Advanced Drug Research (CADRE) based in Harrisonburg, Virginia. The center focuses on state-of-the-art pharmaceutical research. SRI intends to create more than 100 new jobs in the region over the course of 10 years. SRI's Virginia expansion is in partnership with the Commonwealth of Virginia, Rockingham County, the City of Harrisonburg, JMU, and other Virginia institutions of higher education. Until its new offices are completed, SRI is operating out of JMU facilities.

Prior to SRI, Moos served as chairman and chief executive officer of MitoKor (now Migenix), as vice president of research and development in the technologies division of Chiron (now Novartis), and as vice president of neuroscience and biological chemistry at Warner-Lambert/Parke-Davis (now Pfizer). Moos holds a doctorate in chemistry from the University of California, Berkeley, and received a bachelor's degree in chemistry from Harvard University. He has held adjunct faculty positions at the University of Michigan, Ann Arbor, and since 1992 has been an adjunct professor at the University of California, San Francisco.

Moos' talk is sponsored by the JMU student chapter of the Virginia Biotechnology Association.

About SRI's Biosciences Division

SRI International's Biosciences Division teams with pharmaceutical and biotechnology companies, academia, foundations, and government agencies to solve important problems in global health. SRI Biosciences conducts basic research, drug discovery, and drug development, including contract research. SRI has all of the resources necessary to take R&D programs from "idea to IND"™ -- from initial discovery to investigational new drug applications to start human clinical trials -- and specializes in cancer, immunology, infectious disease, and neuroscience research. To date, SRI has helped advance more than 100 drugs into clinical trials, including a number of its own discoveries, several of which have reached the market. SRI is also working at the nexus of science and technology to create new technology platforms for the next generation of drug discovery and development in areas such as diagnostics, drug delivery, medical devices, and systems biology.

About SRI International

Silicon Valley-based SRI International (www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute in 1946, SRI has been meeting the strategic needs of clients for more than 60 years. The nonprofit research institute performs client-sponsored research and development for government agencies, commercial businesses, and private foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships, and creates spin-off companies.

Contact Information

  • Media Contacts:
    Eric Gorton
    James Madison University
    (540) 568-3674
    Email Contact

    Ellie Javadi
    SRI International
    (650) 859-4874
    Email Contact